Cala Health, Inc. - In a recent post-market analysis the Transcutaneous Afferent Patterned Stimulation or TAPS therapy was evaluated for the management of upper limb essential tremor (ET) in a cohort of
![Cala Health® on Twitter: "Exciting news from Cala Health: The #FDA has granted Breakthrough Device Designation to #CalaTrio for the treatment of action tremors in the hands of adults with #ParkinsonsDisease. Read Cala Health® on Twitter: "Exciting news from Cala Health: The #FDA has granted Breakthrough Device Designation to #CalaTrio for the treatment of action tremors in the hands of adults with #ParkinsonsDisease. Read](https://pbs.twimg.com/media/Ek8hJa4XgAAmYK5.jpg)
Cala Health® on Twitter: "Exciting news from Cala Health: The #FDA has granted Breakthrough Device Designation to #CalaTrio for the treatment of action tremors in the hands of adults with #ParkinsonsDisease. Read
Cala Health, Inc. - Cala Health raises $50 Million in Series C funding investment that will fund the commercial introduction of Cala Trio and expansion of the therapeutic platform. Learn more at
![Covid-19. Ils conçoivent un bracelet distributeur de gel hydroalcoolique - Saint-Nazaire.maville.com Covid-19. Ils conçoivent un bracelet distributeur de gel hydroalcoolique - Saint-Nazaire.maville.com](https://maville.com/photosmvi/2020/11/09/P24045659D4368672G.jpg)